Cargando…
Correction: Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations
Autores principales: | Yalon, Michal, Tuval-Kochen, Liron, Castel, David, Moshe, Itai, Mazal, Inbal, Cohen, Osher, Avivi, Camila, Rosenblatt, Kineret, Aviel-Ronen, Sarit, Schiby, Ginette, Yahalom, Joachim, Amariglio, Ninette, Pfeffer, Raphael, Lawrence, Yaacov R., Toren, Amos, Rechavi, Gideon, Paglin, Shoshana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993487/ https://www.ncbi.nlm.nih.gov/pubmed/27548061 http://dx.doi.org/10.1371/journal.pone.0161799 |
Ejemplares similares
-
Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations
por: Yalon, Michal, et al.
Publicado: (2016) -
Eukaryotic Initiation Factor 2α - a Downstream Effector of Mammalian Target of Rapamycin - Modulates DNA Repair and Cancer Response to Treatment
por: Tuval-Kochen, Liron, et al.
Publicado: (2013) -
MutT homolog 1 counteracts the effect of anti-neoplastic treatments in adult and pediatric glioblastoma cells
por: Versano, Ziv, et al.
Publicado: (2018) -
Pediatric glioblastoma cells are sensitive to drugs that inhibit eIF2α dephosphorylation and its phosphomimetic S51D variant
por: Eytan, Karin, et al.
Publicado: (2022) -
Related to testes-specific, vespid and pathogenesis protein-1 is regulated by methylation in glioblastoma
por: JACOBY, ELAD, et al.
Publicado: (2014)